FCN-338
Phase 1Small molecule
FCN-338 is one of 9 small molecule programs targeting CLL/SLL. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
8 competitors in CLL/SLL
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 3
Calquence
AstraZenecaPhase 3
Venclexta
AbbViePhase 2
Lisaftoclax
Ascentage Pharma Group Inc.Phase 3
DZD8586
DDizal Pharmaceuticals
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 2
SYNCAR-001
SSynthekine
Phase 1
STK-009
SSynthekine
Phase 1
FCN-338
FFochon Pharmaceuticals, Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FCN-338. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- FFochon Pharmaceuticals, Ltd.